506387 TumorGenesis® Transformed Breast Media (Ince BMI-T) (Liquid)


Transformed Breast Media (Ince

TRANSFORMED BREAST CELL LINES Transformed with hTERT-gfp + LT/st BPLE1 Breast Luminal BPLE2 Breast Luminal BPLE3 Breast Luminal BPLE4 Breast Luminal

TUMORIGENIC BREAST CELL LINES Transformed with hTERT-gfp + LT/st + H-Ras BPLER1 Breast Luminal BPLER2 Breast Luminal BPLER3 Breast Luminal BPLER4 Breast Luminal

Tan A. Ince, MD, PhD – Fighting Cancer by Keeping Cancer Cells Alive … https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/

Feb 12, 2017 – Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.

SKU: 506387 Category:

EU Commodity Code

Shipping Temp
Blue Ice

Storage Temp
4°C Do Not Freeze

Red to orange, clear, complete liquid

As reported

Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.

Country of Origin
United States

BMI-T Bullet Included (506387B)
Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506387.

Storage (506387B) 
Vial is stable at -20°C. Once thawed and added to 506386, the complete media is stable for 6 weeks at 4°C when stored in the dark.

Licensed by TumorGenesisTM. Manufactured for research use by US Biological

1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...|https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/|2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337|3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90.|4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419.|5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.